Patients, payers, and paradigm shifts: what to do about Helicobacter pylori.
Wolman
S L
SL
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans
D000900:Anti-Bacterial Agents